Anirudh Sattiraju, PhD
Anirudh Sattiraju (Preferred Name)
About Me
Dr. Anirudh Sattiraju is uniquely positioned with expertise in uncovering fundamental biology of glioblastoma, the most lethal brain cancer, and in developing strategies to translate these discoveries for cancer patient care. Through multidisciplinary research, Dr. Sattiraju has deciphered tumor-immune interactions in glioblastoma by employing novel genetic tools in combination with latest transcriptomic technologies, identified crucial biomarkers of disease states, developed biomarker-targeted molecular and cellular therapies and evaluated innovative drug delivery strategies for future use in patient care.
As a postdoctoral fellow, Dr. Sattiraju led investigations that discovered dynamic temporospatial sequestration of tumor associated macrophages and cytotoxic T cells in hypoxic niches during glioblastoma progression, which were subsequently found to be reprogrammed for immunosuppression. Hypoxic niche factors CCL8 and IL-1β, along with host immune status, were found to modulate this immune spatial patterning in glioblastoma. (Sattiraju A et al. Immunity 2023, cover article-August 2023 issue). As a PhD student, he led studies that demonstrated therapeutic efficacy of a novel immunoradiotherapy targeted to Interleukin-13 Receptor Alpha-2 and developed innovate strategies to enhance systemic drug access to glioblastoma (Sattiraju A et al. Molecular Cancer Therapeutics 2017, Sattiraju A et al. Oncotarget 2017).
Dr. Sattiraju is committed to furthering our understanding of devastating cancers and to developing new treatments that can improve patient survival and quality of life.
Language
Position
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
About Me
Dr. Anirudh Sattiraju is uniquely positioned with expertise in uncovering fundamental biology of glioblastoma, the most lethal brain cancer, and in developing strategies to translate these discoveries for cancer patient care. Through multidisciplinary research, Dr. Sattiraju has deciphered tumor-immune interactions in glioblastoma by employing novel genetic tools in combination with latest transcriptomic technologies, identified crucial biomarkers of disease states, developed biomarker-targeted molecular and cellular therapies and evaluated innovative drug delivery strategies for future use in patient care.
As a postdoctoral fellow, Dr. Sattiraju led investigations that discovered dynamic temporospatial sequestration of tumor associated macrophages and cytotoxic T cells in hypoxic niches during glioblastoma progression, which were subsequently found to be reprogrammed for immunosuppression. Hypoxic niche factors CCL8 and IL-1β, along with host immune status, were found to modulate this immune spatial patterning in glioblastoma. (Sattiraju A et al. Immunity 2023, cover article-August 2023 issue). As a PhD student, he led studies that demonstrated therapeutic efficacy of a novel immunoradiotherapy targeted to Interleukin-13 Receptor Alpha-2 and developed innovate strategies to enhance systemic drug access to glioblastoma (Sattiraju A et al. Molecular Cancer Therapeutics 2017, Sattiraju A et al. Oncotarget 2017).
Dr. Sattiraju is committed to furthering our understanding of devastating cancers and to developing new treatments that can improve patient survival and quality of life.
Language
Position
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
